You are here: Industry Insights > Santen

News List

Santen and Sydnexis partner on childhood myopia treatment SYD-101 pharmatimes
August 11, 2021
Santen and Sydnexis have announced an exclusive agreement to license SYD-101, an investigational treatment for progressive childhood myopia, in Europe, Middle East and Africa (EMEA).
Santen and US ophthalmic company Eyevance enter into share purchase agreement pharmaceutical-business-review
September 22, 2020
Santen Pharmaceutical and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of ...
JCyte signs ex-US licensing deal with Santen for retinal disease therapy pharmaceutical-business-review
May 13, 2020
JCyte has signed an ex-US licensing deal with Japanese ophthalmic company Santen Pharmaceutical worth up to $252m to develop and commercialise its investigational jCell therapy for a rare genetic eye disorder called retinitis pigmentosa.
DE-122 flops in wet AMD trial pharmatimes
March 12, 2020
Tracon Pharmaceuticals and Santen have decided to halt development of DE-122 for wet age-related macular degeneration (AMD), after reviewing recently obtained top-line data from the Phase IIa AVANTE clinical study.
OXB and Santen to develop gene therapy products for retinal disease pharmaceutical-technology
June 27, 2019
Oxford Biomedica (OXB) and Santen Pharmaceutical have agreed to jointly conduct research and development (R&D) activities for gene therapy products.
Santen, Glaukos collaborate for exclusive distribution of the MicroShunt in the U.S. biospectrumasia
April 29, 2019
The agreement stipulates that upon potential U.S. regulatory approval, Glaukos will be the exclusive distributor of the MicroShunt in the United States, responsible for sales and distribution of the product.
Santen to raise disease awareness during World Glaucoma Week biospectrumasia
March 08, 2019
During WGW this March, Santen plans to conduct various awareness-raising activities focusing on the disease
Scottish Medicines Consortium approves Verkazia for severe eye condition in children and adolescents pharmafile
December 13, 2018
UK-based pharmaceutical firm Santen has announced that the Scottish Medicines Consortium has awarded approval to its eye drops emulsion Verkazia (ciclosporin) for the treatment of severe vernal keratoconjunctivitis (VKC)...
Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments americanpharmaceuticalreview
February 24, 2017
Santen, Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., the specialty ophthalmology company headquartered in Osaka, Japan, and twoXAR, Inc., an artificial intelligence-driven biopharmaceutical company, announced that the two companies have e